Oncology

Latest News

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

September 6th 2025

Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com
NOTCH1 Levels Impact Immune Response in SCLC

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe
Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

August 31st 2025

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com
Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

August 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
September 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
August 3rd 2016

Nivolumab Passes QOL Test in Melanoma

Surabhi Dangi-Garimella, PhD
Results from the CheckMate 066 study found that the checkpoint inhibitor nivolumab performs well in improving patients' long-term quality of survival benefit in patients with advanced melanoma.
Site Logo
August 2nd 2016

The Risk of T2D in Individuals With Benign Adrenal Tumors

AJMC Staff
Adrenal gland tumors that are defined as being nonfunctional may not really be so, and the hormones that these tumors secrete could increase an individual’s risk of cardiometabolic irregularities, according to a new study.
Site Logo
August 1st 2016

Research and Clinical Updates on World Lung Cancer Day

Surabhi Dangi-Garimella, PhD
World Lung Cancer Day is a grassroots effort conceived by a lung cancer survivor. Here are a few updates on ways to prevent the disease and manage treatment.
This Week in Managed Care: July 30, 2016
July 30th 2016

This Week in Managed Care: July 30, 2016

This week, the top stories in managed care included the release of Medicare's Star ratings for hospital quality, a new proposal from CMS to require bundled payments for cardiac care, and an FDA panel recommended approving a continuous glucose monitoring system for dosing insulin.
Site Logo
July 29th 2016

Women Confident of Breast Cancer Treatment Decisions Following Online Support

Surabhi Dangi-Garimella, PhD
Sharing information of diagnosis and treatment decisions reassured women newly diagnosed with breast cancer of their health choices, according to a new study published in JAMA Oncology.
Site Logo
July 28th 2016

Combining Local Peripheral Treatment With Ipilimumab Doubles Survival in Melanoma

Surabhi Dangi-Garimella, PhD
A new study has found that combining ipilimumab with local peripheral treatments such as radiotherapy or electrochemotherapy can significantly better survival in patients with melanoma.
The Value of Patient Assistance Programs
July 28th 2016

The Value of Patient Assistance Programs

Do Accelerated Review and Narrow Indications Influence Payer Decisions?
July 28th 2016

Do Accelerated Review and Narrow Indications Influence Payer Decisions?

Clinical Pathways
July 28th 2016

Clinical Pathways

Appropriate Use of Companion Versus Complementary Diagnostics
July 28th 2016

Appropriate Use of Companion Versus Complementary Diagnostics

Influence of Biomarkers in Immunotherapy Treatment Decisions
July 28th 2016

Influence of Biomarkers in Immunotherapy Treatment Decisions

Payer Stance on Immunotherapy in Oncology Care
July 28th 2016

Payer Stance on Immunotherapy in Oncology Care

Importance of Patient Assistance Programs in Oncology
July 28th 2016

Importance of Patient Assistance Programs in Oncology

Do Oncologists Contemplate Patient Cost Sharing?
July 28th 2016

Do Oncologists Contemplate Patient Cost Sharing?

Value Benchmarks in Immuno-Oncology
July 28th 2016

Value Benchmarks in Immuno-Oncology

The Unmet Need in Immuno-Oncology and New Drug Approvals
July 28th 2016

The Unmet Need in Immuno-Oncology and New Drug Approvals

Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints
July 28th 2016

Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints

Improving Patient Access-Rapid Approval and Patient Assistance Programs
July 28th 2016

Improving Patient Access-Rapid Approval and Patient Assistance Programs

Combination Therapies: What Works Best for Immuno-Oncology?
July 28th 2016

Combination Therapies: What Works Best for Immuno-Oncology?

Payer Concerns With Including Novel Immunotherapies on Clinical Pathways
July 28th 2016

Payer Concerns With Including Novel Immunotherapies on Clinical Pathways

Combination Immunotherapies in Melanoma
July 28th 2016

Combination Immunotherapies in Melanoma

Understanding Immunotherapy Efficacy and Safety
July 28th 2016

Understanding Immunotherapy Efficacy and Safety

Clinical Pathway Consideration and Payer Decisions
July 28th 2016

Clinical Pathway Consideration and Payer Decisions

Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma
July 28th 2016

Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma

Clinician Concerns with Adopting Clinical Pathways
July 28th 2016

Clinician Concerns with Adopting Clinical Pathways

Health Plan Perspectives on Clinical Pathways
July 28th 2016

Health Plan Perspectives on Clinical Pathways

Clinical Pathways Should Keep Pace With New Data
July 28th 2016

Clinical Pathways Should Keep Pace With New Data

Distinguishing Between Companion and Complementary Diagnostic Tests
July 28th 2016

Distinguishing Between Companion and Complementary Diagnostic Tests

Health Plan Coverage of Diagnostic Tests for PD-L1 Expression
July 28th 2016

Health Plan Coverage of Diagnostic Tests for PD-L1 Expression

Predictive Biomarker Testing for Immunotherapy in Melanoma
July 28th 2016

Predictive Biomarker Testing for Immunotherapy in Melanoma

<1
...
979899100101102103104105
...
188>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo